491 related articles for article (PubMed ID: 3005335)
1. Disialogangliosides GD2 and GD3 are involved in the attachment of human melanoma and neuroblastoma cells to extracellular matrix proteins.
Cheresh DA; Pierschbacher MD; Herzig MA; Mujoo K
J Cell Biol; 1986 Mar; 102(3):688-96. PubMed ID: 3005335
[TBL] [Abstract][Full Text] [Related]
2. Disialoganglioside GD2 distributes preferentially into substrate-associated microprocesses on human melanoma cells during their attachment to fibronectin.
Cheresh DA; Klier FG
J Cell Biol; 1986 May; 102(5):1887-97. PubMed ID: 3084502
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro.
Kawashima I; Tada N; Fujimori T; Tai T
J Biochem; 1990 Jul; 108(1):109-15. PubMed ID: 2121721
[TBL] [Abstract][Full Text] [Related]
4. Human melanoma cell attachment involves an Arg-Gly-Asp-directed adhesion receptor and the disialoganglioside GD2.
Cheresh DA
Prog Clin Biol Res; 1989; 288():3-24. PubMed ID: 2470110
[TBL] [Abstract][Full Text] [Related]
5. An Arg-Gly-Asp-directed receptor on the surface of human melanoma cells exists in an divalent cation-dependent functional complex with the disialoganglioside GD2.
Cheresh DA; Pytela R; Pierschbacher MD; Klier FG; Ruoslahti E; Reisfeld RA
J Cell Biol; 1987 Sep; 105(3):1163-73. PubMed ID: 2443507
[TBL] [Abstract][Full Text] [Related]
6. Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.
Kusano A; Ohta S; Shitara K; Hanai N
Anticancer Res; 1993; 13(6A):2207-12. PubMed ID: 8297135
[TBL] [Abstract][Full Text] [Related]
7. Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells.
Cheresh DA; Harper JR; Schulz G; Reisfeld RA
Proc Natl Acad Sci U S A; 1984 Sep; 81(18):5767-71. PubMed ID: 6385004
[TBL] [Abstract][Full Text] [Related]
8. Synergism between membrane gangliosides and Arg-Gly-Asp-directed glycoprotein receptors in attachment to matrix proteins by melanoma cells.
Burns GF; Lucas CM; Krissansen GW; Werkmeister JA; Scanlon DB; Simpson RJ; Vadas MA
J Cell Biol; 1988 Sep; 107(3):1225-30. PubMed ID: 2458363
[TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated killer cells targeted by monoclonal antibodies to the disialogangliosides GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin.
Honsik CJ; Jung G; Reisfeld RA
Proc Natl Acad Sci U S A; 1986 Oct; 83(20):7893-7. PubMed ID: 3094017
[TBL] [Abstract][Full Text] [Related]
10. Structural and immunological characterization of O-acetylated GD2. Evidence that GD2 is an acceptor for ganglioside O-acetyltransferase in human melanoma cells.
Sjoberg ER; Manzi AE; Khoo KH; Dell A; Varki A
J Biol Chem; 1992 Aug; 267(23):16200-11. PubMed ID: 1644805
[TBL] [Abstract][Full Text] [Related]
11. Different fine binding specificities of monoclonal antibodies to disialosylganglioside GD2.
Tai T; Kawashima I; Tada N; Dairiki K
J Biochem; 1988 Apr; 103(4):682-7. PubMed ID: 3170507
[TBL] [Abstract][Full Text] [Related]
12. Ganglioside antigens in tissue sections of skin, naevi, and melanoma--implications for treatment of melanoma.
Hersey P
Cancer Treat Res; 1991; 54():137-51. PubMed ID: 1673856
[TBL] [Abstract][Full Text] [Related]
13. Recombinant antibodies against ganglioside expressed on tumor cells.
Hanai N; Nakamura K; Shitara K
Cancer Chemother Pharmacol; 2000; 46 Suppl():S13-7. PubMed ID: 10950141
[TBL] [Abstract][Full Text] [Related]
14. Biologic roles of gangliosides G(M3) and G(D3) in the attachment of human melanoma cells to extracellular matrix proteins.
Nakano J; Yasui H; Lloyd KO; Muto M
J Investig Dermatol Symp Proc; 1999 Sep; 4(2):173-6. PubMed ID: 10536995
[TBL] [Abstract][Full Text] [Related]
15. Kinetic and spatial interrelationships between ganglioside glycosyltransferases and O-acetyltransferase(s) in human melanoma cells.
Sjoberg ER; Varki A
J Biol Chem; 1993 May; 268(14):10185-96. PubMed ID: 8486686
[TBL] [Abstract][Full Text] [Related]
16. Immunization with a mimotope of GD2 ganglioside induces CD8+ T cells that recognize cell adhesion molecules on tumor cells.
Wierzbicki A; Gil M; Ciesielski M; Fenstermaker RA; Kaneko Y; Rokita H; Lau JT; Kozbor D
J Immunol; 2008 Nov; 181(9):6644-53. PubMed ID: 18941255
[TBL] [Abstract][Full Text] [Related]
17. Modulation of interactions of neuroblastoma cell lines with extracellular matrix proteins affects their sensitivity to treatment with the anti-GD2 ganglioside antibody 14G2a.
Horwacik I; Rokita H
Int J Oncol; 2017 May; 50(5):1899-1914. PubMed ID: 28393238
[TBL] [Abstract][Full Text] [Related]
18. Potential to involve multiple effector cells with human recombinant interleukin-2 and antiganglioside monoclonal antibodies in a canine malignant melanoma immunotherapy model.
Helfand SC; Soergel SA; Donner RL; Gan J; Hank JA; Lindstrom MJ; Sondel PM
J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):188-97. PubMed ID: 7834118
[TBL] [Abstract][Full Text] [Related]
19. A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies.
Ye JN; Cheung NK
Int J Cancer; 1992 Jan; 50(2):197-201. PubMed ID: 1730513
[TBL] [Abstract][Full Text] [Related]
20. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells.
Lloyd KO; Gordon CM; Thampoe IJ; DiBenedetto C
Cancer Res; 1992 Sep; 52(18):4948-53. PubMed ID: 1516051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
